CE / CME
On-demand webcast of an expert faculty presentation and strategies to improve patients’ brain health through engagement and risk management as a measure to prevent cognitive decline.
Physician Assistants/Physician Associates: 1.75 AAPA Category 1 CME credits
Nurses: 1.75 Nursing contact hours
Physicians: maximum of 1.75 AMA PRA Category 1 Credits™
ABIM MOC: maximum of 1.75 Medical Knowledge MOC points
Released: January 27, 2025
Expiration: January 26, 2026
Share
Provided by Clinical Care Options, LLC
Supported by an educational grant from Lilly.
Lilly
This activity is intended for healthcare professionals who care for patients at risk for cognitive decline, including physicians, nurse practitioners, and physician associates who practice in primary care, general neurology, psychiatry, and OB-GYN practice settings.
The goal of this activity is to improve the knowledge, competence, and performance of learners in effort to improve practices for brain health preservation and prevention of cognitive decline.
Upon completion of this activity, participants should be able to:
Assess the benefits of optimizing brain health to prevent cognitive decline before it occurs
Analyze the evidence for the use of testing to detect AD pathology before symptoms emerge
Implement effective practices for discussing brain health and cognitive decline prevention with patients during routine care
Evaluate for known modifiable risk factors for cognitive decline and dementia at patient visits
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Alireza Atri, MD, PhD
Chief Medical Officer, Banner Research
Phoenix, Tucson and Sun City, Arizona
Director, Banner Sun Health Research Institute
Sun City, Arizona
Alireza Atri, MD, PhD: researcher (paid to institution): Alzheon, Athira, Biohaven, Biogen, Eisai, Lilly, Vivoryon; consultant/advisor: AriBio, Axsome, Eisai, Lantheus, Life Molecular Imaging, Lundbeck, Merck, Novo Nordisk, ONO, Prothena, Vaxxinity.
Sharon A. Brangman, MD
Distinguished Service Professor
Chair, Department of Geriatrics
Director, Upstate Center of Excellence for Alzheimer's Disease
SUNY Upstate Medical University
Syracuse, New York
Sharon A. Brangman, MD: consultant/advisor/speaker: Eisai.
Sharon Cohen, MD, FRCPC
Behavioral Neurologist
Medical Director and Site Principal Investigator
Toronto Memory Program
Toronto, Ontario, Canada
Sharon Cohen, MD, FRCPC: researcher: AbbVie, AgeneBio, Alector, Alnylam, Alzheon, Anavex, Biogen, Cassava Sciences, Eisai, GlaxoSmithKline, INmune Bio, Janssen, Lilly, Novo Nordisk, RetiSpec, Roche, UCB Biopharma; consultant/advisor/speaker: Alnylam, Biogen, Biohaven, Bristol Myers Squibb, Cassava Sciences, Cognivue, Cogstate, Eisai, GlaxoSmithKline, INmune Bio, Kisbee Therapeutics, Lilly, Lundbeck, Novartis, Novo Nordisk, Parexel, RetiSpec, Roche, SciNeuro Pharmaceuticals.
Anton P. Porsteinsson, MD
William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine
Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE)
University of Rochester School of Medicine and Dentistry
Rochester, New York
Anton P. Porsteinsson, MD: other financial or material support: Acadia, Athira, Axsome, Biogen, Bristol Myers Squibb, Eisai, Lundbeck, Novartis, ONO, Otsuka, Xenon; researcher (paid to institution): Alector, Athira, Biogen, Cassava, DOD, Eisai, Genentech/Roche, Lilly, Vaccinex; advisory board: Alzheon, Athira, Cognition Therapeutics; data and safety monitoring board: Acadia, Bristol Myers Squibb.
Elizabeth Poynor, MD, PhD
Chair of Women's Health and Gynecology
Atria Health Institute
New York, New York
Elizabeth Poynor, MD, PhD, has no relevant financial relationships to disclose.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Michael Asbach, DMSc, PA-C, as noted below.
Michael Asbach, DMSc, PA-C: consultant/advisor/speaker: AbbVie, Axsome, Bristol Myers Squibb, Intra-Cellular Therapies, Janssen, Neurocrine, Otsuka, Sage/Biogen, Teva.
Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 27, 2025, through January 26, 2026:
Login or Sign Up for an account by clicking at the top of this page.
Read the target audience, learning objectives, and faculty disclosures.
View and study the content in its entirety.
Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.75 contact hours.
Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.75 AAPA Category 1 CME credits. Approval is valid until January 26, 2026. PAs should only claim credit commensurate with the extent of their participation.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).
CME Passport
The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.